

Sir,

Reply to Chhablani

We thank Dr Chhablani¹ for his interest in our article²; we evaluated diffuse diabetic macular oedema and obtained good functional and anatomic results during a follow-up of 12 months after treatment with intravitreal bevacizumab, when compared with the combination of intravitreal triamcinolone and laser photocoagulation. We agree that intravitreal bevacizumab lacks in large randomized controlled trials and could be used in case of gross macular oedema in order to reduce macular thickening, followed by laser photocoagulation. The latter remains indeed the gold standard for diabetic macular oedema.

Conflict of interest

The authors declare no conflict of interest.

References

- 1 Chhablani JK. Anti-VEGF (vascular endothelial growth factor) drugs in diabetic macular oedema. *Eye* 2010 (e-pub ahead of print 10 December 2010; doi:10.1038/eye.2010.182).
- 2 Forte R, Cennamo GL, Finelli M, Farese E, D'Amico G, Nicoletti G *et al.* Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. *Eye* 2010; **24**(8): 1325–1330.

R Forte, GL Cennamo, M Finelli, E Farese, G D'Amico, G Nicoletti, G de Crecchio and G Cennamo

Eye Department, University Federico II, Naples, Italy
E-mail: raifor@hotmail.com

Eye advance online publication, 10 December 2010;
doi:10.1038/eye.2010.183